Advantages of XXXX repair.

@entity1 @entity6 @entity937 @entity1713 @entity548 @entity2286 @entity260 @entity2790 @entity61897
PURPOSE: To evaluate the outcomes and complications of @entity1 with @entity1713 ( @entity1713 ) treated with pars plana vitrectomy ( @entity2286 ). @entity1 AND METHODS: We retrospectively studied a case series of 24 eyes of 21 @entity1 at a single tertiary, university-affiliated medical center. A review was carried out on @entity1 who underwent @entity2286 for the management of @entity1713 due to proliferative @entity6 from October 2011 to November 2013. Preoperative and final visual outcomes, @entity260 , and medical background were evaluated. RESULTS: @entity61897 instrumentation was used in 23 eyes (95.8%), and a 25 G instrumentation in one (4.2%). Mean postoperative follow-up time was 13.3 months (4-30 months). Visual acuity significantly improved from logarithm of the minimum angle of resolution (LogMAR) 1.48 to LogMAR 1.05 (P<0.05). Visual acuity improved by >= 3 lines in 75% of @entity1 . Intraoperative complications included @entity937 in seven eyes (22.9%) and vitreal @entity548 in nine eyes (37.5%). In two eyes, one sclerotomy was enlarged to 20 G (8.3%). @entity260 included reoperation in five eyes (20.8%) due to persistent subretinal fluid (n=3), @entity548 (n=1), and @entity2790 (n=1). Thirteen @entity1 (54.2%) had postoperative @entity548 that cleared spontaneously, five @entity1 (20.8%) required antiglaucoma medications for @entity2790 , seven @entity1 (29.2%) developed an epiretinal membrane, and two @entity1 (8.3%) developed a macular hole. CONCLUSION: @entity1 with @entity1713 can benefit from @entity2286 surgery. Intraoperative and @entity260 can be attributed to the complexity of this disease.
